IDM PHARMA COMPLETES ENROLLMENT IN IMMUNOTHERAPY TRIAL

IDM Pharma recently announced the completion of patient enrollment in two Phase II clinical trials of Uvidem, IDM's therapeutic product for the treatment of melanoma being developed in collaboration with sanofi-aventis. Thirty-eight patients with malignant melanoma were enrolled in the U.S. study, and 53 patients with resected Stage II/III melanoma were enrolled in the European study.

The U.S. clinical trial is designed to assess the safety and clinical activity of Uvidem in patients with Stage III or IV melanoma with measurable lesions. The primary objective of the European trial is the evaluation of a specific immune response against tumor antigens following treatment with Uvidem, administered with or without peginterferon alpha-2b, in patients with resected Stage II/III melanoma. Secondary objectives are safety and disease-free survival.

Uvidem is a therapeutic specific immunostimulant developed by IDM in partnership with sanofi-aventis, and sanofi-aventis has worldwide marketing rights to Uvidem in melanoma. Uvidem consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. Uvidem, in various phases of clinical development, has so far been injected into 143 patients.